Antigen Detection assay for the Diagnosis of Melioidosis

诊断类鼻疽的抗原检测分析

基本信息

  • 批准号:
    9084470
  • 负责人:
  • 金额:
    $ 70.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-06-15 至 2019-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Burkholderia pseudomallei is a Gram-negative bacterium that is the causative agent of melioidosis. The bacterium causes significant morbidity and mortality in tropical regions and endemic areas are expanding. Melioidosis is difficult to trea and diagnose due to the fact that B. pseudomallei is resistant to common antibiotics and symptoms are non-specific. Mortality rates reach 45% and 20% in Thailand and Australia respectively, even with antibiotic treatment. Currently, there is no validated diagnostic product for the diagnosis of melioidosis. Culturing of patient samples is the "gold standard" for diagnosis; however this can take 3-7 days. Our goal is to develop a rapid point-of-care lateral flow immunoassay (LFI) for the detection of the B. pseudomallei capsular antigen (CPS) directly from patient samples. Phase I STTR Specific Aims focused on producing a library of anti-CPS monoclonal antibodies (mAbs), optimizing the LFI components and sample preparation, and performing a feasibility study on archived melioidosis patient samples. The objectives of this Phase II application is advanced development and validation of the prototype AMD LFI that incorporates a higher affinity CPS mAb. By completing these goals we hope to produce an optimized LFI that possesses sensitivity equal to or greater than culturing of patient samples. To achieve these goals we have established an experienced team. A strong partnership exists between Dr. AuCoin's laboratory and InBios International that has led to the development of an encouraging prototype LFI. In addition, both groups will work closely with experts in endemic areas (Thailand and Australia) who will be conducting a large preclinical evaluation of the LFI with different patient sample types.
描述(申请人提供):假腮腺伯克霍尔德氏菌是一种革兰氏阴性细菌,是类鼻疽的病原体。这种细菌在热带地区造成严重的发病率和死亡率,流行区正在扩大。类鼻疽病很难治疗和诊断,因为假鼻疽杆菌对常见的抗生素具有耐药性,而且症状是非特异性的。即使接受抗生素治疗,泰国和澳大利亚的死亡率也分别高达45%和20%。目前,还没有用于诊断类鼻疽病的有效诊断产品。患者样本培养是诊断的“金标准”;然而,这可能需要3-7天。我们的目标是开发一种快速的护理点横向流动免疫分析法(LFI),用于直接从患者样本中检测假鼻疽囊膜抗原(CPS)。第一阶段STTR的具体目标是生产抗CPS单抗(MAbs)文库,优化LFI成分和样品制备,并对归档的类鼻疽患者样本进行可行性研究。这一第二阶段应用的目标是高级开发和验证AMD LFI原型,该原型结合了更高亲和力的CPS单抗。通过完成这些目标,我们希望生产出一种优化的LFI,其灵敏度等于或高于患者样本的培养。为了实现这些目标,我们建立了一支经验丰富的团队。Aucoin博士的实验室和InBios International之间存在着强有力的合作伙伴关系,这导致了令人鼓舞的LFI原型的开发。此外,两个小组将与流行地区(泰国和澳大利亚)的专家密切合作,后者将对不同患者样本类型的LFI进行大规模临床前评估。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Detection and Quantification of the Capsular Polysaccharide of Burkholderia pseudomallei in Serum and Urine Samples from Melioidosis Patients.
  • DOI:
    10.1128/spectrum.00765-22
  • 发表时间:
    2022-08-31
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    DeMers, Haley L.;Nualnoi, Teerapat;Thorkildson, Peter;Hau, Derrick;Hannah, Emily E.;Green, Heather R.;Pandit, Sujata G.;Gates-Hollingsworth, Marcellene A.;Boutthasavong, Latsaniphone;Luangraj, Manophab;Woods, Kate L.;Dance, David;AuCoin, David P.
  • 通讯作者:
    AuCoin, David P.
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David P AuCoin其他文献

David P AuCoin的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David P AuCoin', 18)}}的其他基金

Enrichment and validation of urine and serum-specific antigens from acute Lyme disease patient samples
急性莱姆病患者样本中尿液和血清特异性抗原的富集和验证
  • 批准号:
    10539304
  • 财政年份:
    2021
  • 资助金额:
    $ 70.01万
  • 项目类别:
Enrichment and validation of urine and serum-specific antigens from acute Lyme disease patient samples
急性莱姆病患者样本中尿液和血清特异性抗原的富集和验证
  • 批准号:
    10373787
  • 财政年份:
    2021
  • 资助金额:
    $ 70.01万
  • 项目类别:
Point-of-care antigen detection assay for early diagnosis of Ebola virus disease (EVD)
用于早期诊断埃博拉病毒病 (EVD) 的即时抗原检测分析
  • 批准号:
    9910131
  • 财政年份:
    2020
  • 资助金额:
    $ 70.01万
  • 项目类别:
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum
人类和非人类伯氏疏螺旋体诊断生物标志物的鉴定
  • 批准号:
    8783365
  • 财政年份:
    2014
  • 资助金额:
    $ 70.01万
  • 项目类别:
Identification of Borrelia burgdorferi diagnostic biomarkers in humans and nonhum
人类和非人类伯氏疏螺旋体诊断生物标志物的鉴定
  • 批准号:
    8892078
  • 财政年份:
    2014
  • 资助金额:
    $ 70.01万
  • 项目类别:
Antigen Detection Assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
  • 批准号:
    8490302
  • 财政年份:
    2012
  • 资助金额:
    $ 70.01万
  • 项目类别:
Antigen Detection assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
  • 批准号:
    8883363
  • 财政年份:
    2012
  • 资助金额:
    $ 70.01万
  • 项目类别:
Antigen Detection Assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
  • 批准号:
    8394825
  • 财政年份:
    2012
  • 资助金额:
    $ 70.01万
  • 项目类别:
Antigen Detection assay for the Diagnosis of Melioidosis
诊断类鼻疽的抗原检测分析
  • 批准号:
    8780682
  • 财政年份:
    2012
  • 资助金额:
    $ 70.01万
  • 项目类别:
Antigenemia immunoassay for point of care dianostic melioidosis
抗原免疫分析用于诊断类鼻疽病的护理点
  • 批准号:
    8260262
  • 财政年份:
    2011
  • 资助金额:
    $ 70.01万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.01万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 70.01万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.01万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.01万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.01万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.01万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 70.01万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 70.01万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 70.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 70.01万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了